General Biologicals Corporation (TPEX:4117)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
4.970
-2.780 (-35.87%)
Mar 10, 2026, 11:50 AM CST
-73.28%
Market Cap 471.39M
Revenue (ttm) 251.38M
Net Income (ttm) -243.60M
Shares Out 60.83M
EPS (ttm) -4.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,405,108
Average Volume 306,649
Open 7.750
Previous Close 7.750
Day's Range 3.500 - 7.820
52-Week Range 3.670 - 24.900
Beta 0.50
RSI 16.87
Earnings Date Apr 24, 2026

About General Biologicals

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. Additionally, it offers a range of oral care products... [Read more]

Sector Healthcare
Founded 1984
Employees 81
Stock Exchange Taipei Exchange
Ticker Symbol 4117
Full Company Profile

Financial Performance

In 2024, General Biologicals's revenue was 251.93 million, a decrease of -4.87% compared to the previous year's 264.83 million. Losses were -220.82 million, 11.1% more than in 2023.

Financial Statements

News

There is no news available yet.